Table 2: Characteristics of randomized controlled trial included in review.

Author
(year)
Subjects Type of PD Amendment Outcomes
Quirynen et al. (1995)
[2]
10 SCP Initial Protocol
(FMS + CHX 2wks)
For deep pockets : more reduction of PPD in T group / C group (p < 0.05).
Bollen et al. (1998)
[5]
16 SCP FMS with CHX 2mths better results than in initial FMD protocol.
Quirynen et al. (2000)
[6]
36 SCP FMD without CHX
FMS alone > QRSP: more reduction of PPD and CAL gain (p<0.001; p <0.001).
Apatzidou et al. (2004)
[7]
40 SCP FMD without CHX Both therapies (FMS alone and QRSP) improved clinical indices.
Quirynen et al. (2006)
[10]
71 MCP FMD with AF Less reduction of PPD with AF alone
( FMS + AF < FMS + CHX or / FMS + CHX +AF p<0.05) .
Wang et al. (2006)
[11]
36 CP FMD with PId
Less reduction of Pg and Aa with Id versus Water or QRSP (p<0.005;P<0.005).
Gomi et al. (2007)
[14]
34 SCP FMD + AZT alone
Significant improvement of clinical parameters with AZT (PPD, BOP, GCF) (P<0.001).
Cavalca al. (2009)
[12]
50 MCP FMD with EO Efficacy of EO to reduce PPD, PI and BOP.
Cortelli et al. (2009)
[13]
50 MCP FMD with EO At 2 and 6 months, no significance difference between EO and placebo regarding microbiology parameters.
Yashima et al. (2009)
[15]
30 CP FMD + AZT alone Significant improvement of clinical parameters with AZT (P<0.01; P<0.05).
Cionca et al. (2009)
[16]
47 CP FMD + Amox & MTZ
At 6 months, less sites with PDP > 4 mm with Amox +MTZ versus placebo.

Swierkot et al. (2009)
[8]
25 CP FMD without CHX At 1 and 2 months, more reduction of PPD, BOP in FMD with or without CHX versus QRSP alone.
Cionca et al. (2010)
[17]
51 CP FMD + Amox & MTZ Significant reduction of Pg (P = 0,013) and Tf (P = 0,007) with FMD combined to Amox&MTZ compared to placebo or FMD alone.
Sigusch et al. (2010)
[23]
24 CP FMD with PTD Better improvements of PPD and CAL gain with FMD combined to PTD versus FMD alone.

Varela et al. (2011)
[18]
25 AP FMD + Amox & MTZ Better clinical improvements (PPD, CAL) on sites with PDi <5mm (p <0.03) using FMD combined to Amox&MTZ versus FMD alone.
Aimetti et al. (2012)
[19]
39 AP FMD + Amox & MTZ Up to 6 months, better reduction of Aa + red complexes in site with PDi > 5 mm using FMD combined to Amox&MTZ versus FMD alone .
Preus et al. (2013)
[20]
184 MCP & SCP FMD + MTZ alone Up to 12 months in groups with MTZ, sites with PDi > 5 mm obtained better PPD reduction + better CAL gain.
Santos et al. (2013)
[9]
38 CP FMD without CHX Up to 12 months similar clinical improvement with or without CHX.
Teughels et al. (2013)
[21]
30 CP FMD + PRB12 wks Reduction in surgical treatment need with PRB.
Keestra et al. (2014)
[24]
24 CP FMD + periodontal dressing Reduction of postoperative pain with adjunction of periodontal dressing .
Fonseca et al. (2015)
[22]
85 CP FMD + AZT Addition of AZT did not provide additional clinical benefit compared to the FMD technique alone.

+: associated to; &: and ; Amox :Amoxicillin ; AZT :Azithromycin; AF:Amine Fluoride; AP :Agressive Periodontitis; BOP, Bleeding On Probing ; CAL, Clinical Attachment Level; CHX:Chlorhexidine; CHX 2months : Chlorhexidine during 2 months; CHX 2wks : Chlorhexidine during 2 weeks ; CP : Chronic Periodontitis ; EO :Essential Oils ; FMD : Full Mouth Disinfection ; FMS : Full Mouth Scaling; GCF :Gingival Crevicular Fluid. H2O: water; MCP: Moderate Chronic Periodontitis; MTZ: Metronidazole; PD:Periodontitis ; PDi : Initial Probing Depth; Pg :Porphyrhomonas Gingivalis ; PId Povidone Iodine PI, Plaque Index; PPD, Probing Pocket Depth; PRB12 wks :Probiotics During 12 weeks;PTD:Photodynamic Therapy; QSRP:Conventional Treatment by Quadrant ;RCT: Randomized Control Trial ;SCP:Severe Chronic Periodontitis

Back to Article